Innovative Therapy: Access Code
National healthcare priorities focus on improving citizens’ well-being, finding cures for difficult-to-cure diseases, increasing quality of life, and extending life expectancy. They also aim to promote widespread access to innovative drug treatments, gene therapy, and biomedical cell products. Global practices in securing access to modern drugs, however, present a number of difficulties. Besides regulatory barriers that prevent new drugs from coming to the market, developing innovative drugs requires substantial investment, which is reflected in their market price. Strategies for promoting drug innovations in clinical trials are tied to models of drug supply, among which the system of shared risk has been successfully used in international practice. In order to improve the supply of innovative drugs in Russia, a number of programmes need to be put in place to aid the development of a full manufacturing cycle infrastructure. There also need to be a range of incentives for domestic manufacturers of innovative drugs. No less important is the strategy of building long-term mutually beneficial partnerships on the pharma market. What innovative products and technologies will drive the development of present-day and future medicine? What initiatives will be able to stimulate the development of an innovative pharma industry that is attractive to investors, and which will promote the unhindered supply of innovative drugs on the market? What regulatory decisions may help stimulate research and development in Russia? Will the “odd man out” rule become the stimulus for supporting Russian innovations, or a threat to the competitive model of the pharma market? How well does the register of pharmacologically active substances support the goals of protecting the reputation of commercialized generics on the one hand, and protecting the intellectual property rights of the inventors of the original drugs on the other? How can the balance between the generics and innovation industries be maintained? How will the strategy of increasing export-oriented production impact the development of innovative technologies in Russia?
Yekaterina Gracheva, Anchor, Russia 24 TV Channel
Sultana Afdhal, Chief Executive Officer, World Health Innovation Summit (WISH)
Sergey Glagolev, Deputy Minister of Health of the Russian Federation
Alisa Dzhangiryants, Director of Market Access and Pricing, Bristol-Myers Squibb (online)
Grigory Ivliev, Head, Federal Service for Intellectual Property (Rospatent)
Oksana Monge, General Manager Sanofi Eurasia, Chair of the Board of Directors, AIPM
Alla Samoylova, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)
Evgeny Shlyakhto, Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"
Front row participants
Sergey Kutsev, Director, Research Centre for Medical Genetics; Chief External Expert in Medical Genetics of the Ministry of Health of the Russian Federation
Наталья Мокрышева, Director, National Medical Research Center for Endocrinology Ministry of Health of the Russian Federation
Daniil Taliansky, General Director, "Generium"